Zymeworks Inc reports results for the quarter ended in June - Earnings Summary

Zymeworks

01/08/2024 23:41

* Zymeworks Inc  ZYME.OQ  reported a quarterly adjusted loss
of 27
cents​​ per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of -76
cents.  The mean expectation of seven analysts for the quarter
was for a loss of 32 cents per share. Wall Street expected
results to range from -48 cents to 28 cents per share.
    * Revenue rose 174.8% to $19.24 million from a year ago;
analysts
expected $20.09 million. 
    * Zymeworks Inc's reported EPS for the quarter was a loss
of 49
cents​.
    * The company reported a quarterly loss of $37.69 million.
    * Zymeworks Inc shares had risen by 22.9% this quarter and
gained 0.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 184.9% in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Zymeworks Inc is
$14.00 
This summary was machine generated from LSEG data August 1 at
10:40 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.32          -0.27          Beat
 Mar. 31 2024      -0.29          -0.42          Missed
 Dec. 31 2023      -0.43          -0.20          Beat
 Sep. 30 2023      -0.47          -0.41          Beat